Pelletizer is Designed for Die-Face Cutting of Hot-Melt Extruded Drugs
The Leistritz LHLG series air-quench pelletizer mates with an extruder and enables die-face cutting of pellets in air for water-soluble pharmaceutical formulations.
The Leistritz LHLG pelletizer on the ZSE-18 twin-screw extruder. Image courtesy of Leistritz.
The Leistritz LHLG series air quench pelletizer mates with an extruder and enables die-face cutting of pellets in air for water-soluble, highly filled, and foamed formulations that are typically used for pharmaceutical and nutraceutical products. The die is electrically heated, and the flow geometry is matched with the formulation and throughput rate. The die, blades, and all contact areas are fabricated of hardened stainless, tool, and carbide steels. Standard features include:
- Electrically heated pelletizing die
- Self-aligning cutter hub with replaceable blades driven by AC motor
- Manually adjusted blades for allowable wear
- Stainless-steel cutting chamber with sight glass and safety interlock
- Height-adjustable support cart on tracks
- Optional, chamber-misting attachments for sticky formulations.
A blower facilitates initial cooling and transport to a secondary cooling and transport mechanism, such as high-velocity venturi blowers, vacuum systems, cyclones, and vibratory cooling/classification equipment. GMP-class systems are available for medical and pharmaceutical environments.
Leistritz has installed LHLG pelletizers in its New Jersey process laboratory to test formulations for use with its ZSE-18, ZSE-27, and ZSE-50 MAXX model twin-screw extruders.
Source: Leistritz
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
